Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumacaftor/Ivacaftor in CF with A455E Mutation
NCT03061331Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lumacaftor, ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Jan 2017; status: completed.
02
Drugs
lumacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03061331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03061331.